Cue Biopharma, Inc. (CUE)
US — Healthcare Sector
Automate Your Wheel Strategy on CUE
With Tiblio's Option Bot, you can configure your own wheel strategy including CUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CUE
- Rev/Share 0.1076
- Book/Share 0.0886
- PB 7.3973
- Debt/Equity 1.0828
- CurrentRatio 1.0279
- ROIC -3.0011
- MktCap 49391859.0
- FreeCF/Share -0.4697
- PFCF -1.4161
- PE -1.1993
- Debt/Assets 0.3202
- DivYield 0
- ROE -2.2843
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
CUE
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025.
Read More
About Cue Biopharma, Inc. (CUE)
- IPO Date 2018-01-02
- Website https://www.cuebiopharma.com
- Industry Biotechnology
- CEO Mr. Daniel R. Passeri J.D., M.Sc.
- Employees 41
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.